Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Adjuvant chemotherapy for ctDNA positive patients- Randomized phase II study of comparing FOLFOX6 with FOLFOXIRI+Bevaxcizumab

ABSTRACT: Interventions: At enrollment, each subject will be assigned to one of the following treatment groups mFOLFOXIRI + BV therapy every 2 weeks for up to 8 cycles, followed by maintenance therapy for a total of up to 12 cycles. mFOLFOX6 therapy every 2 weeks for up to12 cycles.;C410216, C509829, D000068258;mFOLFOX6, mFOLFOXIRI, bevacizumab, mFOLFOX6 Primary outcome(s): the percentage of ctDNA negative conversion Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose

DISEASE(S): Positive Ctdna, Colorectal Cancer, Oligometastasis,Patients With Positive Ctdna After Curative Resection For Metastasis Of Colorectal Cancer

PROVIDER: 97707 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Prediction of response to FOLFOX

Project description:The patients who underwent surgery for primary lesions were examined. All patients had metastatic or recurrent CRC and received modified FOLFOX6. Responders and nonresponders were determined based on the best observed response at the end of the first-line treatment, mFOLFOX6. Gene-expression profiles of primary CRC were determined using Human Genome GeneChip arrays U133. Colorectal cancer patients who had undergone surgical resection of colorectal cancer were studied. To identify molecular signatures to predict response to mFOLFOX6 regimen, gene expression profiles were compared between Reponder and Non-responder. Some patients are overlapped with Bevacizumab therapy.

2013-01-03 | E-GEOD-19860 | biostudies-arrayexpress

A Multicenter, Clinical Phase II study of FOLFOXIRI with Bevacizumab As First-line Therapy in Patients with Metastatic Colorectal Cancer.

Project description:Interventions: [Induction treatment:FOLFOXIRI+BV] Administered for a maximum of 12 cycles. BV: 5mg/kg (d.i.v.) L-OHP: 85 mg/sq.m (d.i.v.) CPT-11:165mg/sq.m (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks. [Maintenance treatment:5-FU/LV+BV] BV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks. Primary outcome(s): Progression-free survival (PFS) at 10 months; by investigator-reported measurements. Study Design: Single arm Non-randomized

| 2629147 | ecrin-mdr-crc

mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Project description:Colorectal cancer patients with initially unresectable liver-only metastases may be cured after downsizing of metastases by conversion therapy. However, the optimal regimen of conversion therapy for RAS mutant patients has not been defined. In this study colorectal cancer patients with initially unresectable liver-only metastases, as prospectively confirmed by a local multidisciplinary team (MDT) according to predefined criteria, will be tested for RAS and BRAF tumor mutation status. Patients with RAS mutant and BRAF wild type will be randomised between modified FOLFOXIRI (mFOLFOXIRI) plus bevacizumab and modified FOLFOX6 (mFOLFOX6) plus bevacizumab. Patient imaging will be reviewed for resectability by MDT, consisting of at least one radiologist and three liver surgeons every assessment. MDT review will be performed prior to randomization as well as during treatment, as described in the protocol.

| 2369422 | ecrin-mdr-crc

Effect of bacterial vaginosis, Lactobacillus and Premarin estrogen replacement therapy on vaginal gene expression changes.

Project description:The aim of the study was to investigate gene expression profiles of post-menopausal women receiving Premarin estrogen replacement therapy (ERT), compared to controls and to examine any correlations between the bacterial vaginosis (BV) status of the stubjects. This is the first study to use gene arrays to correlate changes in host expression to ERT and BV.

2018-04-28 | GSE113771 | GEO

mFOLFOXIRI for oligometastatic CRC

Project description:Interventions: [First step eligible patients] 1)Surgery based on the principle of each site. Second step surgery for primary tumor and metastatic tumor(s) are alllowed 2)Blood exam for cfDNA/ctDNA analysis at four points; before surgery, 28days after surgery, 4 months after surgery and 7 months after surgery [Second step eligible patients] mFOLFOXIRI therapy (8 cycles maximum) mFOLFOXIRI administered every 2 weeks for 8 cycles maximum 1. 90min infusion of irinotecan 150 mg/m2 (day1) 2. 2-hour infusion of oxaliplatin 85 mg/m2 and levofolinate 200 mg/m2(day1) 3. 48-hour continuous infusion (day2-3) [Maintenance therapy (4 cycles)] 1) 2-hour infusion of levofolinate 200 mg/m2 2) 48-hour continuous infusion of fluorouracil 2400 mg/m2;C509829;FOLFOXIRI Primary outcome(s): Treatment compliance (at 8 cycles) Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2615381 | ecrin-mdr-crc

Expression data from the brain of Mus musculus upon intrastriatal administration of baculoviral vectors

Project description:Recombinant insect baculoviral vectors (BV) efficiently transduce several types of cells in the brain and can possibly be used for gene therapy for brain disorders. To verify the suitability of using these viral vectors to develop gene therapy strategies in the brain, and to evaluate our method of virus purification, we evaluated immune reactions upon acute administration of BV that were purified by ion-exchange membrane chromatography with high-speed centrifugation or high-speed centrifugation alone into the mouse brain using microarray global gene expression profiling.

2015-11-21 | GSE75265 | GEO

Liver resection after chemotherapy for liver only metastasis from colorectal cancer

Project description:Interventions: Chemotherapy with modified FOLFOX6 plus BV(bevacizumab). Treatment repeats every 14 days for up to 6 courses (5 courses for BV) in the absence of disease progression or unacceptable toxicity. Liver resection (if possible, 4 to 8 weeks after modified FOLFOX6 plus BV) Primary outcome(s): Curative resection rate (R0 resection rate) [in all subjects] Study Design: Single arm Non-randomized

| 2617582 | ecrin-mdr-crc

Elimination of Teratogenic Human Induced Pluripotent Stem Cells by Bee Venom via calcium-calpain pathway

Project description:Induced pluripotent stem cells (iPSCs) are regarded as a promising option for cell-based regenerative medicine. To obtain safe and efficient iPSC-based cell products, it is necessary to selectively eliminate the residual iPSCs prior to in vivo implantation to eliminate the risk of teratoma formation. Bee venom (BV) has long been used in traditional Chinese medicine to treat inflammatory diseases and relieve pain, and has been shown to exhibit anti-cancer, anti-mutagenic, anti-nociceptive, and radioprotective activities. However, the potential benefits of BV in iPSC therapy, particularly its anti-teratoma activity, have not been examined. In this study, we tried to measure the effects of BV on expression of genes in iPSCs.

2020-04-10 | GSE148378 | GEO

Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma

Project description:The purpose of this study is to exploratorily examine efficacy and safety in the participants with chemotherapy-naïve unresectable, advanced/recurrent colorectal carcinoma of Kirsten rat sarcoma-2 virus (KRAS) wild-type who have been treated with 6 cycles (2 weeks/cycle) of first-line mFOLFOX6 + panitumumab combination therapy and then assigned to two groups i.e., a group receiving 5-FU/LV + panitumumab combination therapy and a group receiving mFOLFOX6 + panitumumab combination therapy.

| 2181884 | ecrin-mdr-crc

mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer

Project description:This study will focus on postoperative patients of stage IIIB or stage IIIC colorectal cancer. These patients will start to accept chemotherapy in 3-4 weeks after operation, these patients were randomly divided into two groups, one group will accept adjuvant chemotherapy of mFOLFOX6 or CapeOX; another group will use mFOLFOXIRI, they can change the regimen to mFOLFOX6 or CapeOx after accepting not less than two complete chemotherapy regimen, if can not tolerate the adverse reaction of mFOLFOXIRI. The efficacy and safety of adjuvant chemotherapy will be compared between the two groups. Disease-free survival, overall survival, incidence of adverse reaction of chemotherapy and postoperative quality of life will be recorded.

| 2401641 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data